All Stories

  1. BDNF-related brain–liver communication in metabolic syndrome: implications for anxiety and depression
  2. Homeobox genes in endocrine tumorigenesis: mechanisms, tumor microenvironment interaction, and therapeutic potential
  3. Programmed cell death in kidney disease: integrated crosstalk among ferroptosis, pyroptosis, apoptosis, and cuproptosis
  4. Ischemic Heart Disease in G20 Countries: Forecasted Burden and Regional Disparities Based on GBD 2023 Estimates
  5. The Mediating Role of Atherogenic Index of Plasma in the Association Between Dietary Inflammatory Index and Metabolic Syndrome: Evidence from NHANES and CHARLS
  6. Rising Global Burden and Sex Disparities in Nonmelanoma Skin Cancer: 1990-2021 Trends With Projections to 2036
  7. Inflammatory and hormonal crosstalk linking rheumatic fever to chronic valvular heart disease
  8. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
  9. Regulated cell death pathways in endocrine tumor plasticity: A narrative review
  10. Immunometabolic Remodeling in Ischemic and Non-Ischemic Heart Failure
  11. Regional Inequities in Metabolic Dysfunction–associated Steatotic Liver Disease Burden and Care Quality in High-burden Settings: Implications for Health Systems
  12. Targeting Ferroptosis and Pyroptosis in Cardiovascular Diseases: Mechanisms and Therapeutic Implication
  13. From AKI to CKD mechanisms of maladaptive repair and disease progression
  14. Trends and determinants of childhood anxiety disorders burden in Asia, 1990–2023
  15. Natural Monomer Compounds in Neurodegenerative Diseases: Targeting Ferroptosis and Neuroinflammation
  16. Global, Regional and National Burden of Pulmonary Arterial Hypertension in Young and Middle-Aged Adults, 1990–2021, with Projections to 2045
  17. RNA methylation in cardiovascular remodeling: Molecular mechanisms, biomarkers, and therapeutic strategies
  18. Regional disparities and metabolic determinants of type 2 diabetes in women aged 55 and older
  19. Temporal patterns and predictive factors of depressive disorders among adolescents and young people in Asia
  20. miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential
  21. The gut-brain axis in diabetic neuropathy, cognitive impairment, and emotional disorders
  22. STAT Signaling in Metabolic Disorders: From Molecular Mechanisms to Therapeutic Implications
  23. Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
  24. Global Trends and Projections in Chronic Kidney Disease Burden from Diabetes, Hypertension, and Glomerulonephritis: A Population-Based Study
  25. Microbiota-Targeted Modulation of the Gut–Kidney Axis in Diabetic Kidney Disease: Therapeutic Advances and Future Perspectives
  26. Temporal Patterns and Predictive Factors of Childhood Depressive Disorders Across Asia
  27. Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
  28. Association between cardiometabolic index and thyroid function: insights from NHANES
  29. The Role of Lactate Metabolism in Tumors
  30. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  31. Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential
  32. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
  33. Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990–2021: a systematic analysis of the global burden of disease study
  34. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential
  35. Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseases
  36. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  37. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  38. METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential
  39. The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease
  40. Editorial: Novel approaches to diet, exercise, and drugs in childhood obesity and metabolic diseases
  41. Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with ty...
  42. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
  43. Multimodal Neuroimaging of Brain Structure, Metabolism, and Function in Obesity: Current Landscape and Future Perspectives
  44. Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
  45. Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021
  46. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
  47. The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study
  48. Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045
  49. Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and Mechanisms
  50. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies
  51. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
  52. Nutritional Influences on Brown and Beige Adipocyte: Unraveling the Molecular Mechanisms and Metabolic Implications
  53. Associations between visceral adipose index, lipid accumulation products, and thyroid function parameters in U.S. Adults: analysis of NHANES data
  54. Exploring the Therapeutic Role of Pregnane X Receptor Activation in Acute Kidney Injury: Mechanisms and Clinical Implications
  55. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
  56. Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential
  57. KRAS Mutations in Cancer
  58. Updated Insights on Childhood Diabetes Epidemiology 2019-2021 and Projections to 2045
  59. Revolutionizing public health through digital health technology
  60. Exploring heparin’s protective mechanism against AGEs induced endothelial injury
  61. Editorial: Metabolic diseases and healthy aging: prevention and public health policy based on risk factors
  62. The influence of perceived formative assessment on the learning autonomy of medical students: the chain mediating role of psychological empowerment and positive academic emotions
  63. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation
  64. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities
  65. Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice
  66. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
  67. Metagenomic and metabolomic analysis showing the adverse risk–benefit trade-off of the ketogenic diet
  68. Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review
  69. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
  70. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  71. Epidemiology of 369 diseases and injuries attributable to 84 risk factors: 1990–2019 with 2040 projection
  72. Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
  73. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3‐mediated Wnt/β‑catenin signaling pathway
  74. Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
  75. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions
  76. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
  77. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health
  78. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  79. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019
  80. Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling
  81. Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
  82. Role of dysfunctional peri-organ adipose tissue in metabolic disease
  83. Editorial: Incretin agonists in the treatment of obesity
  84. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
  85. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019
  86. Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling
  87. Editorial: Clinical and genetic determinants of diabetes and complications
  88. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules
  89. Editorial: The impact of adipose tissue dysfunction on cardiovascular and renal disease, Volume II
  90. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019
  91. Editorial: Aging and chronic disease: public health challenge and education reform
  92. NTRK fusions in thyroid cancer: Pathology and clinical aspects
  93. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019
  94. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)
  95. Case report: Maturity-Onset Diabetes of the Young (MODY12) caused by ABCC8 gene mutations
  96. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
  97. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
  98. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on Expression of FAM3 Members
  99. Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer
  100. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
  101. Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
  102. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
  103. Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects
  104. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  105. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
  106. COL1A1: A novel oncogenic gene and therapeutic target in malignancies
  107. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus
  108. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
  109. Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
  110. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
  111. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension
  112. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
  113. Doctor of Public Health-Crisis Management and COVID-19 Prevention and Control: A Case Study in China
  114. Online Education Plight and Countermeasures for MBBS in Chinese Regional Medical Schools Based on the OBE Concept During COVID-19 Pandemic
  115. Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
  116. Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway
  117. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related lncRNAs in Lung Adenocarcinoma
  118. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
  119. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
  120. A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
  121. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  122. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis
  123. Comprehensive overview of human serum albumin glycation in diabetes mellitus
  124. DL‑3‑n‑butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation
  125. The analgesic efficacy of extracorporeal shock wave combined with percutaneous vertebroplasty in the treatment of osteoporotic thoracolumbar compression fractures in postmenopausal women
  126. Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
  127. How to recognize and respond to viral re-positivity and disease relapse in patients with COVID-19
  128. Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
  129. Attaching clinical significance to COVID-19-associated diarrhea
  130. Identification of Potential Indicators for Survival in Patients With Thyroid Cancer Based on Mrna Expression Levels of Family With Sequence Similarity 3 Members
  131. Liraglutide improves obesity‐induced renal injury by alleviating uncoupling of the glomerular VEGF–NO axis in obese mice
  132. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China
  133. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin
  134. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion
  135. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease
  136. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis
  137. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
  138. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  139. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
  140. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on mRNA Expression Levels of Family with Sequence Similarity 3 Members
  141. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
  142. A Meta-Analysis of Pregnancy Outcomes with Levothyroxine Treatment in Euthyroid Women with Thyroid Autoimmunity
  143. AMPK: a balancer of the renin–angiotensin system
  144. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
  145. AMPK: a therapeutic target of heart failure—not only metabolism regulation
  146. Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
  147. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice
  148. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice
  149. Irisin Improves Endothelial Dysfunction through Perivascular Adipose Tissue
  150. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice
  151. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway
  152. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats
  153. Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway
  154. Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
  155. The relationship between circulating irisin levels and endothelial function in lean and obese subjects
  156. Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats
  157. Perirenal fat associated with microalbuminuria in obese rats
  158. Effect of high free fatty acids on the anti-contractile response of perivascular adipose tissue in rat aorta
  159. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats
  160. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients
  161. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro
  162. Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats
  163. Time–Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers
  164. Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients
  165. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  166. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
  167. High free fatty acids level related with cardiac dysfunction in obese rats
  168. Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
  169. Effect of polysaccharides of theEuphoria longan(Lour.) Steud on inflammatory response induced by focal cerebral ischemia/reperfusion injury in rats